Kennedy Capital Management’s Apogee Therapeutics APGE Stock Holding History

Kennedy Capital Management’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.3M	Sell	122,669 -2,310	-2%	-$168K	0.22%	170
2025 Q4	$9.43M	Buy	124,979 +928	+0.7%	+$58.5K	0.2%	176
2025 Q3	$4.93M	Buy	124,051 +48,154	+63%	+$1.84M	0.11%	298
2025 Q2	$3.3M	Sell	75,897 -2,500	-3%	-$95.1K	0.08%	359
2025 Q1	$2.93M	Buy	78,397 +6,090	+8%	+$235K	0.07%	371
2024 Q4	$3.28M	Buy	72,307 +31,113	+76%	+$1.59M	0.07%	410
2024 Q3	$2.42M	Buy	41,194 +8,755	+27%	+$419K	0.05%	477
2024 Q2	$1.28M	Buy	32,439 +29,251	+918%	+$1.42M	0.03%	565
2024 Q1	$212K	Buy	+3,188	New	+$139K	﹤0.01%	702

Other funds holding APGE

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Kennedy Capital Management's APGE Position: Q1 2026 in Review

Kennedy Capital Management reduced its Apogee Therapeutics (APGE) stake by 1.8% in Q1 2026, selling an estimated $168K and leaving 122,669 shares worth $10.3M. The position accounts for 0.22% of the portfolio, ranked #170.

Kennedy Capital Management first reported a position in APGE in Q1 2024 and has held it in 9 quarters since. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

Kennedy Capital Management held 122,669 shares of Apogee Therapeutics worth $10.3M as of Q1 2026.
Kennedy Capital Management sold 2,310 Apogee Therapeutics shares in Q1 2026, an estimated $168K.
Apogee Therapeutics made up 0.22% of Kennedy Capital Management's portfolio in Q1 2026, its #170 holding.
Kennedy Capital Management first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 9 quarters since.
224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Kennedy Capital Management's 13F filing for Q1 2026, filed 13 May 2026.